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Abstract: Hypertension and renal disease are closely related. In fact, there is an inverse linear 
relationship between renal function and prevalence of hypertension. Hypertensive patients 
with renal dysfunction exhibit a poor clinical profile, which markedly increases their risk for 
  cardiovascular outcomes. This review considers the available evidence on the best therapeutic 
approach for optimizing renovascular protection in the hypertensive population. To effectively 
reduce or at least slow the establishment and progression of renal disease in the hypertensive 
population it is critical to reach blood pressure targets. Many studies have shown that angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers prevent or at least delay the 
development of microalbuminuria in patients with hypertension and type 2 diabetes, reduce 
the incidence of overt diabetic nephropathy, and are also beneficial in patients with nondiabetic 
renal disease. Therefore, renin-angiotensin system (RAS) inhibition plays a key role in the pre-
vention of renal outcomes. As the majority of patients with hypertension will need at least two 
antihypertensive agents to achieve blood pressure goals, the use of RAS inhibitors is a manda-
tory part of antihypertensive therapy. The question of which antihypertensive agent is the best 
choice for combining with RAS blockers should be considered. Many studies have shown that 
diuretics and calcium channel blockers are the best choice. However, more studies are needed 
to clarify the subgroups of patients who will benefit more from a combination with a diuretic 
or from a combination with a calcium channel blocker. To date, RAS inhibitors recommended 
in this context are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. 
Aliskiren, the first oral direct renin inhibitor available, has shown promising results.
Keywords: antihypertensive drugs, renin-angiotensin system, angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers, combined therapy
Hypertension and renal disease
Hypertension is the most important modifiable risk factor for cardiovascular disease. 
It has been estimated that about 30% of the general population is hypertensive, 
a   proportion that increases to two-thirds in the elderly.1 Remarkably, this prevalence is 
increased in patients with renal insufficiency. Thus, in a large cohort of Spanish patients 
enrolled in an ongoing prospective, observational, multicenter study of patients with 
stage 3 (n = 434) and 4 (n = 695) chronic kidney disease, hypertension was almost 
universal (91.2% and 94.1%, respectively). Moreover, proteinuria (.300 mg/day) was 
present in more than 60% of patients, without significant differences between stages 
3 and 4 (1.2 ± 1.8 and 1.3 ± 1.8 g/day, respectively).2 In fact, there is an inverse linear 
relationship between renal function and prevalence of hypertension (from 66% at a 
glomerular filtration rate of 83 mL/minute per 1.73 m2 of body surface area to 95% at 
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a glomerular filtration rate of 12 mL/minute per 1.73 m2 of 
body surface area).3 In patients with diabetic nephropathy, 
the prevalence of hypertension ranges from 41% in subjects 
with type 1 diabetes to 93% in those with type 2 diabetes and 
proteinuria.4,5 Therefore, hypertension and kidney health are 
closely related. Hypertension is one of the main causes of 
renal disease, and hypertension is more prevalent in patients 
with a decreased renal function.6
There is an inverse relationship between renal function 
and the risk of cardiovascular disease.7 This relationship was 
first demonstrated in patients with end-stage renal disease. 
Thus, about 40%–75% of patients on dialysis have cardio-
vascular disease, and around 50% of these patients die from 
this condition. Overall, patients with end-stage renal disease 
have an increased risk, up to 20–30 times, of developing 
cardiovascular disease when compared with the general 
population.8–11 There is also a clear relationship between 
moderate renal disease and cardiovascular disease. In the 
HOPE (Heart Outcomes and Prevention Evaluation) study, 
ramipril significantly reduced the rates of death, myocardial 
infarction, and stroke in a broad range of high-risk patients 
who were not known to have a low ejection fraction or 
heart failure. In a post hoc analysis, the risk of myocardial 
infarction was higher for patients with a baseline serum 
creatinine level $1.4 mg/dL (n = 980) than for those with 
a serum creatinine level ,1.4 mg/dL (n = 8307).12 In the 
Hypertension Optimal Treatment study involving 18,597 
patients, at baseline there were 470 patients who had a 
serum creatinine level higher than 1.5 mg/dL. Those patients 
with a high serum creatinine level at randomization more 
frequently had a history of myocardial infarction or other 
sequelae of coronary heart disease, stroke, and diabetes mel-
litus than those with a serum creatinine level #1.5 mg/dL.13 
Moreover, cardiac structure alterations are more frequent 
in patients with renal insufficiency. Thus, left ventricular 
hypertrophy is more common in subjects with a creatinine 
clearance ,30 mL/minute (38%) than in those with a crea-
tinine clearance .30 mL/minute (16%).14
Furthermore, hypertensive patients with renal dysfunction 
exhibit a poor clinical profile, which markedly increases their 
risk for cardiovascular outcomes. Thus, in a study involving 
2024 patients with hypertension and chronic ischemic heart 
disease, those patients with an estimated glomerular filtration 
rate (using the Modification of Diet in Renal Disease study 
formula) ,60 mL/minute per 1.73 m2 of body surface area 
(n = 666; 32.9%) were older and had a higher proportion of 
atrial fibrillation, diabetes, organ damage (left ventricular 
hypertrophy), associated clinical conditions (heart failure, 
cerebrovascular disease), and worse blood pressure (BP) 
control rates.15
The diagnosis of hypertension-induced renal damage in 
hypertensives is based not only on reduced renal function 
but also on increased urinary excretion of albumin.11 This 
is very relevant, as it is well established that any degree of 
albuminuria is associated with a higher risk of cardiovascular 
disease and progression of kidney disease. In fact, there is a 
continuous relationship between urinary albumin excretion 
and cardiovascular disease.16–18 Therefore, a reduced glom-
erular filtration rate and an increased urinary albumin excre-
tion markedly raise cardiovascular risk, particularly so when 
both alterations are present.19 As a result, the prevention of 
development of either microalbuminuria or renal dysfunction 
are two essential targets in patients with hypertension.1,11
Importance of BP control
Hypertension is related not only to the development but also 
to the progression of renal disease. Several studies have ana-
lyzed the factors influencing the progression to chronic renal 
disease. Although many factors such as age, male gender, 
HbA1c in diabetics, smoking, obesity or hypercholesterolemia 
have been involved, BP control and proteinuria are the most 
important.20–22 In the Multiple Risk Factor Intervention Trial, 
which involved 332,544 men between the ages of 35 and 
57 years who were screened between 1973 and 1975, after 
a 16-year follow-up 814 subjects had either died of end-
stage renal disease or were being treated for that condition 
(15.6 cases per 100,000 person-years of observation). A strong, 
graded relationship between both systolic and diastolic BP and 
end-stage renal disease was identified. Moreover, as compared 
with men with an optimal level of BP (,120/80 mmHg), the 
relative risk of end-stage renal disease for those with higher 
BP values ($210/120 mmHg) was 22.1 (P , 0.001).23 In a 
US study performed in California, after 8,210,431 person-
years of follow-up, and on 316,675 subjects with an estimated 
glomerular filtration rate $60 mL/minute per 1.73 m2 of body 
surface area and negative dipstick urinalysis results for pro-
teinuria or hematuria, 1149 cases of end-stage renal disease 
occurred. Compared with subjects with a BP ,120/80 mmHg, 
the relative risks for developing end-stage renal disease 
were 1.62 for BP of 120–129/80–84 mmHg, 1.98 for BP 
of 130–139/85–89 mmHg, 2.59 for BP of 140–159/90–
99 mmHg, 3.86 for BP of 160–179/100–109 mmHg, 3.88 
for BP of 180–209/110–119 mmHg, and 4.25 for BP 
of $210/120 mmHg.22 With regard to BP components, it has 
been observed that systolic BP is a stronger predictor of end-
stage renal disease than diastolic BP or pulse pressure.24
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The Modification of  Diet in Renal Disease study examined 
the effects of dietary protein restriction and strict BP control 
on the decline in glomerular filtration rate in 840 patients with 
diverse renal diseases. In the multivariate analysis, six fac-
tors (greater urine protein excretion, diagnosis of polycystic 
kidney disease, lower serum transferrin, higher mean arte-
rial pressure, black ethnicity, and lower serum high-density 
lipoprotein cholesterol) independently predicted a faster 
decline in glomerular filtration rate. A low BP intervention 
was found to have greater benefit in patients with higher 
levels of baseline urine protein.20 Different meta-analyses 
have shown in diabetics and nondiabetics that BP control 
slows progression of renal disease.25,26 A meta-analysis by 
Jafar et al26 analyzed eleven randomized controlled trials 
comparing the efficacy of antihypertensive regimens with 
or without angiotensin-converting enzyme (ACE) inhibitors 
for patients with predominantly nondiabetic kidney disease. 
The paper reported that a systolic BP goal between 110 and 
129 mmHg may be beneficial in patients with urine protein 
excretion levels greater than 1.0 g/day. However, a systolic 
BP ,110 mmHg may be associated with a higher risk of 
kidney disease progression.26
All these data emphasize the importance of attaining BP 
goals in the hypertensive population to avoid or at least slow 
the development or progression of renal disease. The ques-
tion of what the BP goals should be, not only in the overall 
hypertensive population but also in high-risk patients, should 
be considered. The 2007 European Society of Hypertension–
European Society of Cardiology guidelines for the manage-
ment of arterial hypertension established that BP should be 
reduced to at least ,140/90 mmHg, and to lower values, if 
tolerated, in all hypertensive patients. Target BP should be 
at least ,130/80 mmHg in diabetics and in high- or very-
high-risk patients, such as those with associated clinical 
conditions (stroke, myocardial infarction, renal dysfunction, 
proteinuria).1 The reappraisal of European guidelines, pub-
lished in 2009, indicates that there is sufficient evidence to 
recommend a BP goal below 140/90 mmHg in each hyperten-
sive patient. However, on the basis of current data, it may be 
prudent to recommend lowering BP to values within the range 
130–139/80–85 mmHg, and possibly closer to the lower 
  values in this range, in every hypertensive.27 National Institute 
for Health and Clinical Excellence guidelines recommend a 
BP goal ,140/90 mmHg in the overall hypertensive popula-
tion and ,140/80 mmHg in diabetics (or ,130/80 mmHg 
if kidney, eye, or cerebrovascular damage is present).28 The 
Canadian guidelines establish that in hypertensive patients 
without other compelling indications, the BP goal should 
be ,140/90 mmHg, as well as in hypertensive patients 
with a history of cardiovascular disease (coronary artery 
disease, previous myocardial infarction, heart failure, left 
ventricular hypertrophy, past stroke/transient ischemic attack 
or peripheral arterial disease). In patients with diabetes with/
without albuminuria, nondiabetic chronic kidney disease with 
proteinuria or renovascular disease, the target BP should 
be ,130/80 mmHg.29
A recent systematic review analyzed what should be the 
optimal BP target in patients with chronic kidney disease. 
For this purpose, three trials with a total of 2272 partici-
pants were included. Overall, trials did not show that a BP 
target ,125/75–130/80 mmHg was more beneficial than 
a target of ,140/90 mmHg. Lower-quality evidence sug-
gested that a lower target may be beneficial in subgroups 
with proteinuria .300–1000 mg/day.30
Although BP control rates have improved in recent 
years, there remains a lot of room for improvement. One 
of the most important reasons for the recent improvements 
shown is the higher use of combined therapy. On the other 
hand, as cardiovascular risk increases, a smaller propor-
tion of patients attain BP goals, including those with renal 
  dysfunction (Table 1).31–33
Renin-angiotensin system inhibition 
and renovascular protection
Although the renin-angiotensin-aldosterone system (RAS) 
plays a critical role in human physiology, and although 
angiotensin II, the RAS effector peptide, is essential for the 
homeostatic control of the cardiovascular system (including, 
among others, sodium and water balance, BP control, and cel-
lular growth and replication), the excessive RAS activation is 
markedly associated with the establishment and progression 
of the cardiovascular continuum.6,34,35 In fact, the excessive 
activation of the RAS has been implied in the progression of 
the entire cardiovascular disease continuum, from the early 
Table 1 Percentage of patients who attain blood pressure (BP) goals according to cardiovascular risk and clinical profile
Hypertensive population attended daily by primary care physicians
Clinical condition Low risk Medium risk High risk Diabetes Metabolic syndrome Cardiovascular disease Cardiac disease
BP control rates 37.5% 30.2% 15.4% 6.3% 17.2% 25.3% 27.4%
Note: Data from the PRESCOT (Prevención Cardiovascular en España en Atención Primaria: Intervención Sobre el Colesterol en Hipertensión) study (adapted from Barrios32).
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stages (hypertension and diabetes) to the middle (left ven-
tricular hypertrophy and microalbuminuria) and late stages 
(coronary disease, stroke, heart failure, and renal disease).6
In the case of the kidneys, at the beginning, and through 
different mechanisms such as oxidative stress, angiotensin 
II promotes subclinical damage to glomerular endothelium 
that results in endothelial dysfunction. Thereafter, because 
of vascular sclerosis and the glomerulosclerosis, tubuloint-
erstitial fibrosis, which implies a progressive deterioration 
of the glomerular capillary barrier and the hemodynamic 
abnormalities in the vasculature at the glomerular level, 
microalbuminuria appears. As a result, microalbuminuria 
is an early manifestation of renal damage in patients with 
hypertension, particularly in diabetics. If treatment is not 
applied, renal damage progresses to macroalbuminuria or 
proteinuria. In this context, the glomerular filtration rate 
progressively declines to the final stages of renal disease. 
This gradual decline in renal function is associated with an 
increased risk of cardiovascular disease. Therefore, excess 
angiotensin II production is responsible, at least in part, for 
the establishment and development of hypertension and renal 
damage.6,35–37
However, despite the knowledge about the importance of 
the RAS in the development of cardiovascular disease pro-
vided, at least in part, from experimental data, and despite the 
fact that high renin activity is associated with cardiovascular 
outcomes, the most robust evidence has come from clinical 
trials using ACE inhibitors, angiotensin receptor blockers 
(ARBs) and, in recent years, aliskiren – the first oral direct 
renin inhibitor.6,38–40
Some trials have analyzed the effects of RAS   inhibition 
in the prevention of microalbuminuria in patients with 
  hypertension and type 2 diabetes. The BENEDICT (Bergamo 
Nephrologic Diabetes Complications Trial) study reported that 
in subjects with type 2 diabetes and hypertension but with 
normoalbuminuria, the use of trandolapril plus verapamil 
(5.7%) and trandolapril alone (6.0%) decreased the incidence 
of microalbuminuria to a similar extent. However, the effect 
of verapamil alone (11.9%) was similar to that of placebo 
(10.0%).41 In the ROADMAP (Randomized Olmesartan and 
Diabetes Microalbuminuria Prevention) study, 4447 patients 
with type 2 diabetes and normoalbuminuria were randomized 
to receive olmesartan (at a dose of 40 mg once daily) or placebo 
for a median of 3.2 years. Additional antihypertensive drugs 
(except ACE inhibitors or ARBs) were used as needed to lower 
BP to ,130/80 mmHg. The main results of this study showed 
that the target BP (,130/80 mmHg) was achieved in nearly 
80% of the patients taking olmesartan and in 71% of those 
taking placebo (clinic BP was 3.1/1.9 mmHg lower in the olm-
esartan group than in the placebo group).   Microalbuminuria 
developed in 8.2% of the patients in the olmesartan group and 
in 9.8% of those in the placebo group. Moreover, the time to 
the onset of microalbuminuria was increased by 23% with the 
ARB olmesartan (hazard ratio [HR], 0.77; 95% confidence 
interval [CI], 0.63–0.94; P = 0.01) (Table 2).42
Both ACE inhibitors and ARBs have been shown to 
reduce the incidence of overt diabetic nephropathy. Thus, in 
the 3577 people with diabetes included in the HOPE study, 
ramipril reduced the risk of overt nephropathy by 24% 
(P = 0.027) when compared with placebo, and this effect 
was greater than that attributable to the decrease in BP.43 In 
the Irbesartan in Patients with Type 2 Diabetes and Microal-
buminuria study, irbesartan was shown to be renoprotective 
independently of its BP-lowering effect in patients with 
type 2 diabetes and microalbuminuria.44 In the RENAAL 
(Reduction of Endpoints in Non-Insulin-Dependent Diabe-
tes Mellitus with the Angiotensin II Antagonist Losartan) 
trial, 1513 patients with type 2 diabetes and nephropathy 
were randomized to receive losartan (50–100 mg once 
daily) or placebo, both taken in addition to conventional 
antihypertensive treatment. Over a mean treatment period 
of 3.4 years, the composite primary end point of a dou-
bling of serum creatinine concentration, end-stage renal 
disease, or death occurred in 327 and 359 patients assigned 
to losartan and   placebo, respectively (risk reduction, 16%; 
95% CI, 2%–28%; P = 0.02).45 The   Irbesartan in Diabetic 
  Nephropathy Trial compared the   renoprotective efficacy of 
irbesartan 300 mg, amlodipine 10 mg, and placebo in 1715 
hypertensive patients with   nephropathy caused by type 2 
diabetes. Over the mean follow-up period of 2.6 years, irbe-
sartan reduced the risk of the primary end point (doubling 
of serum creatinine concentration,   end-stage renal disease, 
or death) by 20% when compared with placebo and by 23% 
when compared with amlodipine. The risk of a doubling 
of the serum creatinine concentration was 33% and 37% 
lower with irbesartan than with placebo and amlodipine, 
respectively, and irbesartan also reduced the risk of end-
stage renal disease by 23% compared with either placebo 
or amlodipine.46 More recently, the ORIENT (Olmesartan 
Reducing Incidence of End Stage Renal Disease in Dia-
betic Nephropathy Trial) study   examined the effects of 
olmesartan on the primary   composite outcome of doubling 
serum creatinine concentration,   end-stage renal disease, and 
death in type 2 diabetic patients with overt   nephropathy. 
A total of 577 patients treated with   antihypertensive 
therapy (73.5% received concomitant ACE inhibitors) were 
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included. Although olmesartan was well tolerated, it did 
not improve renal outcome on top of ACE inhibitors.47 
Aliskiren, the last marketed RAS inhibitor, has also been 
tested in this context.48 Thus, the AVOID (Aliskiren in the 
Evaluation of Proteinuria in Diabetes) trial was performed 
to assess the renoprotective effects of dual blockade of the 
RAS by adding treatment with aliskiren to the maximally 
recommended dose of losartan (100 mg daily) and optimal 
antihypertensive therapy in hypertensive patients with type 
2 diabetic nephropathy. Despite a small, not statistically 
significant difference in BP between groups (−2/−1 mmHg 
lower in the aliskiren group), aliskiren reduced the mean 
urinary   albumin-to-creatinine ratio by 20% (P , 0.001) 
(Table 2).40
Some studies have been developed in patients with 
nondiabetic renal disease. Thus, it has been observed that in 
microalbuminuric subjects, treatment with fosinopril has a 
significant effect on urinary albumin excretion.49 In a study 
performed in patients with chronic nephropathies with pro-
teinuria $3 g/day, ramipril safely reduced proteinuria and 
the rate of glomerular filtration rate decline to an extent that 
seemed to exceed the reduction expected for the degree of 
BP lowering.50 The ROAD (Renoprotection of Optimal Anti-
proteinuric Doses) study was aimed to determine whether 
titration of benazepril or losartan to optimal antiproteinuric 
doses would safely improve the renal outcome in nondiabetic 
chronic renal insufficiency. The study showed that optimal 
antiproteinuric dosages of benazepril and losartan, at com-
parable BP control, achieved a greater reduction in both 
proteinuria and the rate of decline in renal function than their 
conventional dosages (Table 2).51
In the ONTARGET (Ongoing Telmisartan Alone and in 
Combination with Ramipril Global Endpoint Trial) study, 
telmisartan was clinically equivalent to ramipril in patients 
Table 2 Relevant studies that have studied the effects of renin-angiotensin system inhibition on renal outcomes
Clinical setting Study Population Commentary
Prevention of microalbuminuria  
in patients with hypertension  
and type 2 diabetes
BENEDICT41 Subjects with type 2 diabetes  
and hypertension but with  
normoalbuminuria
The use of trandolapril plus verapamil (5.7%)  
and trandolapril alone (6.0%) decreased the incidence  
of microalbuminuria to a similar extent 
The effect of verapamil alone (11.9%) was similar  
to that of placebo (10.0%)
ROADMAP42 Patients with type 2 diabetes  
and normoalbuminuria
Microalbuminuria developed in 8.2% of the patients  
in the olmesartan group and 9.8% in the placebo group 
Time to the onset of microalbuminuria was increased  
by 23% with olmesartan (HR, 0.77; P = 0.01)
Reduction of overt diabetic  
nephropathy
HOPE43 Patients of HOPE  
with diabetes
Ramipril reduced the risk of overt nephropathy  
by 24% (P = 0.027) when compared with placebo
IRMA244 Patients with type 2 diabetes  
and microalbuminuria
Irbesartan was shown to be renoprotective independently  
of its BP-lowering effect
RENAAL45 Patients with type 2 diabetes  
and nephropathy
The composite primary end point of doubling of serum  
creatinine concentration, end-stage renal disease,  
or death was reduced with losartan when compared  
with placebo (risk reduction, 16%; P = 0.02)
IDNT46 Hypertensive patients with  
type 2 nephropathy diabetes
Irbesartan reduced the risk of the primary end point  
(doubling of serum creatinine concentration, end-stage  
renal disease, or death) by 20% and 23%, compared  
with placebo and amlodipine, respectively
ORIENT47 Type 2 diabetic patients with  
overt nephropathy
Olmesartan did not improve renal outcome on top  
of ACE inhibitors
AVOID40 Hypertensive patients with  
type 2 diabetic nephropathy
Despite a small, not statistically significant difference  
in BP between groups, aliskiren reduced the mean  
urinary albumin-to-creatinine ratio by 20% (P , 0.001)
Nondiabetic renal disease ROAD51 Patients with nondiabetic  
chronic renal insufficiency
Optimal antiproteinuric dosages of benazepril and losartan,   
at comparable BP control, achieved a greater reduction  
in both proteinuria and the rate of decline in renal function   
than with their conventional dosages
Abbreviations:  ACE,  angiotensin-converting  enzyme;  AVOID,  Aliskiren  in  the  Evaluation  of  Proteinuria  in  Diabetes;  BENEDICT,  Bergamo  Nephrologic  Diabetes 
Complications Trial; BP, blood pressure; HOPE, Heart Outcomes and Prevention Evaluation; HR, hazard ratio; IDNT, Irbesartan in Diabetic Nephropathy Trial; IRMA2, 
Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria; ORIENT, Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial; 
RENAAL, Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan; ROAD, Renoprotection of Optimal Antiproteinuric 
Doses; ROADMAP, Randomized Olmesartan and Diabetes Microalbuminuria Prevention.
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with vascular disease or high-risk diabetes.52 In a substudy 
that specifically analyzed renal outcomes, the composite 
primary outcome (a composite of dialysis, doubling of 
serum creatinine concentration, and death) was similar for 
telmisartan and ramipril (13.4% versus 13.5%, respectively; 
HR, 1.00; 95% CI, 0.92–1.09). The secondary renal outcome, 
dialysis or doubling of serum creatinine concentration, was 
also similar for telmisartan and ramipril (2.21% versus 
2.03%; HR, 1.09; 95% CI, 0.89–1.34). The estimated glom-
erular filtration rate declined least with ramipril compared 
with telmisartan, but the increase in urinary albumin excre-
tion was smaller with telmisartan than with ramipril.53
Although there are unquestionable benefits of RAS inhi-
bition in the prevention of renal complications in the hyper-
tensive population (particularly in diabetics), the majority of 
patients with hypertension, especially those at highest risk, 
will need at least two antihypertensive drugs to attain BP 
goals.1,33 So, since RAS inhibitors are an essential component 
of combined therapy, the next question to be considered is 
which antihypertensive drug should be associated with RAS 
inhibitors to better prevent or at least delay renal outcomes.
Combination of RAS inhibitors  
and diuretics
Diuretics (usually thiazides or thiazide-like indoline diuret-
ics such as indapamide) have been shown to effectively 
reduce BP levels.54 Moreover, in the 13,101 hypertensive 
patients with type 2 diabetes enrolled in the ALLHAT 
(Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial) study, chlorthalidone, a thiazide-type 
diuretic, reduced cardiovascular outcomes to an extent similar 
to lisinopril or amlodipine.55 However, diuretics may cause 
urinary electrolyte wasting and, secondary to this, hypona-
tremia, hypokalemia, and/or hypomagnesemia. Moreover, 
thiazide diuretics may cause metabolic disturbances, particu-
larly at higher doses. Fortunately, the combination of RAS 
inhibitors with thiazide diuretics reduces both electrolyte and 
metabolic disturbances. Furthermore, when side effects are 
present they are generally mild to moderate in severity.6 At 
low doses, thiazide diuretics usually do not cause changes 
in renal function, and they can be used when the estimated 
glomerular filtration rate is .30 mL/minute.54,56
Several studies have analyzed the effects of the combi-
nation of RAS inhibitors and diuretics on renal outcomes. 
Thus, it has been shown that in hypertensive patients with 
stage 3–4 chronic kidney disease, the combination of losartan 
and hydrochlorothiazide significantly reduced the urinary 
protein-to-creatinine ratio, without significant changes in the 
serum creatinine levels and estimated glomerular filtration 
rates. Notably, none of the patients exhibited a significant 
increase in the occurrence of adverse effects.57 Similarly, in 
hypertensive patients with stage 3 chronic kidney disease, 
combination therapy with the maximum recommended daily 
dose of losartan of 100 mg and a low dose of hydrochloro-
thiazide of 12.5 mg ameliorated proteinuria and reduced BP 
more effectively than treatment with losartan 100 mg alone, 
irrespective of whether the patients had diabetes.58 In a study 
that evaluated the changes in BP and urinary protein excretion 
in poorly controlled hypertensive and proteinuric patients 
with mild to moderate chronic kidney disease, patients 
were evaluated after switching from the high-dose ARBs 
to a combination of normal-dose telmisartan (40 mg) and 
low-dose hydrochlorothiazide (12.5 mg). The combination 
of telmisartan and hydrochlorothiazide appeared to be more 
efficacious than a monotherapy of high-dose ARBs in reduc-
ing BP and urinary protein excretion.59
The PREMIER (Preterax in Albuminuria Regression) 
study compared the effects of the combination of perindopril 
2 mg and indapamide 0.625 mg with the effects of enalapril 
monotherapy on albumin excretion rates in patients with type 
2 diabetes, albuminuria, and hypertension in a 12-month, 
international, multicenter, randomized, double-blind, parallel-
group study. Although both treatments reduced BP, the fixed 
combination of perindopril and indapamide resulted in a 
greater, statistically significant fall in both BP (∆systolic 
BP −3.0 mmHg, P = 0.012; ∆diastolic BP −1.5 mmHg, 
P = 0.019) and albumin excretion rate (−42% versus −27%) 
than enalapril. Remarkably, the greater albumin excretion 
rate reduction remained significant after adjustment for 
mean BP (Table 3).60
The ADVANCE (Action in Diabetes and   Vascular 
  Disease: Preterax and Diamicron Modified-Release 
  Controlled Evaluation) trial was performed to assess the 
effects of the fixed combination of perindopril and inda-
pamide on serious vascular events in patients with dia-
betes, irrespective of initial BP levels or the use of other 
BP-lowering drugs. A total of 11,140 patients with type 
2 diabetes were randomized to treatment with the fixed 
combination or matching placebo, in addition to current 
therapy. Compared with the patients assigned placebo, after 
a mean of 4.3 years of follow-up, those assigned to active 
therapy had a mean reduction in systolic BP of 5.6 mmHg 
and diastolic BP of 2.2 mmHg. The relative risk of a major 
macrovascular or microvascular event was reduced by 9% 
(HR, 0.91; 95% CI, 0.83–1.00; P = 0.04). Active treatment 
was associated with a significant 21% reduction in all renal 
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outcomes (P , 0.0001), with a trend in the reduction in new 
or worsening nephropathy (3.3% versus 3.9%; relative risk 
reduction, 18%; P = 0.055), and a significant reduction in 
the development of microalbuminuria (19.6% versus 23.6%; 
relative risk reduction, 21%; P , 0.0001) (Table 3).61
In summary, volume excess has been shown to blunt the 
BP and albuminuria response to RAS inhibitors. Thus, acting 
on volume status by means of diuretic therapy effectively 
reduces BP and albuminuria.62 As a result, the combination 
of RAS inhibitors and diuretics seems to be particularly 
beneficial in hypertensive patients with renal disease.
Combination of RAS inhibitors  
and calcium channel blockers
Combining RAS inhibitors with a calcium channel blocker has 
been shown to effectively reduce BP values.1   Dihydropyridines 
are potent vasodilators that induce reflex activation of the 
RAS. As a result, the concomitant use of ACE inhibitors or 
ARBs may buffer this excessive   activation. Furthermore, 
as calcium channel blockers raise angiotensin II levels, the 
antihypertensive effect of RAS inhibitors   increases.63 Nota-
bly, the combination of calcium channel blockers with RAS 
inhibitors decreases the presence of drug-related side effects, 
particularly peripheral edema.64
Although through the reduction of BP levels calcium 
channel blockers may reduce urinary albumin excretion, 
not all calcium channel blockers are equal, as they differ 
in their effect on glomerular hemodynamics and urinary 
albumin excretion.54 Conventional dihydropyridines block 
only L-type calcium channels. This promotes peripheral 
vasodilatation, including afferent renal arterioles with little 
change in the efferent arteriole diameter, as the efferent 
arterioles lack L-type receptors. Consequently, there is an 
increase of intraglomerular pressure and, secondary to this, 
proteinuria. On the other hand, T-type calcium channel block-
ers are present in both afferent and efferent arterioles. Newer 
calcium   channel blockers such as manidipine block both 
L- and T-type receptors, inducing vasodilatation not only 
Table 3 Relevant studies of the effects of combining diuretics or calcium channel blockers with renin-angiotensin system inhibitors on 
renal outcomes
Clinical setting Study Population Commentary
Diuretics PREMIER60 Patients with type 2 diabetes,  
albuminuria, and hypertension
The combination of perindopril and indapamide, when 
compared with enalapril, resulted in a greater, statistically 
significant fall in both BP (∆systolic BP −3.0 mmHg, P = 0.012; 
∆diastolic BP −1.5 mmHg, P = 0.019) and albumin excretion 
rate (−42% vs −27%)
ADVANCE61 Patients with type 2 diabetes Those patients assigned to active treatment (perindopril-
indapamide) were associated with a significant reduction (21%) 
in all renal events (P , 0.0001), with a trend in the reduction in 
new or worsening nephropathy (P = 0.055) and a significant 
reduction in the development of microalbuminuria (relative risk 
reduction, 21%; P , 0.0001)
Calcium channel  
blockers
AMANDHA66 Type 2 diabetic patients with  
hypertension and microalbuminuria  
uncontrolled with renin-angiotensin  
system blockers
Although manidipine and amlodipine decreased BP values to 
a similar extent, urinary albumin excretion was more greatly 
reduced with manidipine than with amlodipine (65.5% vs 
20%, respectively, P , 0.01 at 6 months; 62.7% vs 16.6%, 
respectively, P , 0.01 at the end of the extension phase  
of 18 months)
CARTER70 Hypertensive patients with  
kidney disease
After 1 year of treatment, despite a similar BP reduction, the 
urinary protein-to-creatinine ratio significantly decreased in the 
cilnidipine group compared with the amlodipine group
DIAL75 Hypertensive patients with  
type 2 diabetes
After 9–12 months of follow-up, both lercanidipine and ramipril 
treatments resulted in a significant reduction in albumin 
excretion rate without a statistically significant difference 
between the two treatments
ACCOMPLISH78 Patients with hypertension and at  
high risk for cardiovascular events
2.0% of the benazepril plus amlodipine group vs 3.7% of 
patients treated with the benazepril plus hydrochlorothiazide 
showed chronic kidney disease progression (HR, 0.52;  
P , 0.0001)
Abbreviations: ACCOMPLISH, Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension; ADVANCE, Action in Diabetes 
and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation; AMANDHA, Efficacy and Tolerance Assessment of Manidipine in Type 2 Diabetic Patients 
with Hypertension and Microalbuminuria Uncontrolled with Renin-Angiotensin System Blockers; BP, blood pressure; CARTER, Cilnidipine versus Amlodipine Randomised Trial 
for Evaluation in Renal Desease; DIAL, Diabete, Ipertensione, Albuminuria, Lercanidipina; HR, hazard ratio; PREMIER, Preterax in Albuminuria Regression; vs, versus.
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in the glomerular afferent arteriole but also in the efferent 
arteriole, resulting in a reduction of proteinuria.54,65–67
Different studies have tested the effects of combining 
calcium channel blockers with RAS inhibitors.65,66,68–79 In 
a 12-week, double-blind study conducted in patients with 
hypertension and type 2 diabetes, patients were randomized 
either to a fixed-dose combination of amlodipine besylate 
and benazepril or to enalapril monotherapy. Although both 
treatments were similarly effective in lowering BP, reduc-
ing systemic vascular resistance, and decreasing urinary 
albumin excretion, those patients treated with combined 
therapy exhibited a significantly greater improvement in 
large-vessel compliance (52% versus 32%; P , 0.05).68 In 
a study comparing the long-term effect of amlodipine and 
fosinopril, either in monotherapy or in combination, on 
urinary albumin excretion, 453 hypertensive patients with 
type 2 diabetes and microalbuminuria were randomized to 
amlodipine (5–15 mg/day), fosinopril (10–30 mg/day), or 
amlodipine plus fosinopril (from 5/10 to 15/30 mg/day) for 
a 3-month titration period. The nonresponder patients or 
those complaining of side effects during the titration period 
were discontinued (n = 144); the remaining 309 patients were 
enrolled in the trial and were treated with the same therapy 
for 4 years. The combination therapy was more effective in 
reducing BP than either drug in monotherapy at any time of 
the study without affecting glucose homeostasis. Although 
the three treatment arms significantly reduced urinary albu-
min excretion during the 48-month study period, this effect 
was more pronounced and became evident earlier with 
fosinopril than with amlodipine monotherapy. Notably, the 
amlodipine-fosinopril combination provided a greater anti-
albuminuric effect than any of the monotherapies, but this 
could be because of the greater antihypertensive effects.69 
The AMANDHA (Efficacy and Tolerance Assessment of 
Manidipine in Type 2 Diabetic Patients with Hypertension 
and Microalbuminuria Uncontrolled with Renin-Angiotensin 
System Blockers) study compared the efficacy and safety of 
adding manidipine 20 mg versus amlodipine 10 mg to the 
treatment of diabetic patients with uncontrolled hyperten-
sion and microalbuminuria despite full-dose treatment with 
a RAS blocker for at least 6 months. Although manidipine 
and amlodipine decreased BP values to a similar extent, 
urinary albumin excretion was more significantly reduced 
with manidipine than with amlodipine (65.5% versus 20%, 
respectively, P , 0.01 at 6 months; 62.7% versus 16.6%, 
respectively, P , 0.01 at the end of the extension phase of 
18 months) (Table 3).66 Cilnidipine is a dual L- and N-type 
calcium channel blocker that dilates both efferent and afferent 
arterioles. In the CARTER (Cilnidipine versus Amlodipine 
Randomised Trial for Evaluation in Renal Desease) study, 
nearly 340 patients with hypertension and kidney disease 
already receiving RAS inhibitor treatment were randomly 
assigned to cilnidipine or amlodipine. After 1 year of treat-
ment, despite a similar BP reduction, the urinary protein-
to-creatinine ratio significantly decreased in the cilnidipine 
group compared with the amlodipine group (Table 3).70
Lercanidipine is a dihydropyridine characterized by its 
high lipophilicity and selectivity for vascular smooth muscle, 
with a gradual and prolonged antihypertensive effect, as 
well as good tolerability, compared with other dihydropyri-
dines.71–74 In the DIAL (Diabete, Ipertensione, Albuminuria, 
Lercanidipina) study, hypertensive patients with type 2 
diabetes were treated with lercanidipine (10–20 mg/day) or 
ramipril (5–10 mg/day). After 9–12 months of follow-up, 
both lercanidipine and ramipril treatments resulted in a 
significant reduction in the albumin excretion rate without a 
statistically significant difference between the two treatment 
groups (Table 3).75 In a study that included 203 patients with 
chronic renal failure (creatinine .1.4 mg/dL for males, 
creatinine .1.2 mg/dL for females, or creatinine clearance 
,70 mL/minute) who were all treated with RAS inhibitors 
(63.4% with ACE inhibitors, 36.6% with ARBs), lercani-
dipine showed a high antihypertensive effect, with a good 
tolerability profile. Notably, creatinine clearance improved 
from 41.8 to 45.8 mL/minute and proteinuria significantly 
decreased from 3.5 to 2.8 g/day.76 In a study that included 68 
proteinuric (.500 mg/day) patients, receiving ACE inhibi-
tors (51.4%) or ARBs (48.6%) but with high BP, the addition 
of lercanidipine 20 mg/day showed a high antihypertensive 
and antiproteinuric effect. This antiproteinuric effect seemed 
to be dose dependent and proportionally higher than BP 
reduction.77
However, the most important trial performed in this 
  context has been a substudy of the ACCOMPLISH (  Avoiding 
Cardiovascular Events through Combination Therapy in 
Patients Living with Systolic Hypertension) trial. This 
study showed that initial antihypertensive therapy with 
benazepril plus amlodipine was superior to benazepril plus 
hydrochlorothiazide in reducing cardiovascular morbidity 
and mortality in 11,506 patients with hypertension who 
were at high risk for cardiovascular events. The effects of 
these drug combinations on progression of chronic kid-
ney disease were assessed in this substudy. Progression 
of chronic kidney disease, a prespecified end point, was 
defined as the doubling of serum creatinine concentration 
or end-stage renal disease (estimated glomerular filtration 
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rate ,15 mL/minute per 1.73 m2 of body surface area or the 
need for dialysis). The trial was prematurely stopped (mean 
follow-up of 2.9 years) because of the superior efficacy of 
benazepril plus amlodipine compared with benazepril plus 
hydrochlorothiazide. With regard to renal end points, 2.0% 
of the benazepril plus amlodipine group versus 3.7% of 
patients treated with benazepril plus hydrochlorothiazide 
showed chronic kidney disease progression (HR, 0.52; 95% 
CI, 0.41–0.65; P , 0.0001). With regard to side effects in 
patients with chronic kidney disease, while peripheral edema 
(33.7% versus 16.0%, for the benazepril plus amlodipine 
group and the benazepril plus hydrochlorothiazide group, 
respectively) and angioedema were more frequent in the 
benazepril plus amlodipine group, dizziness, hypokalemia, 
and hypotension were more frequent in the benazepril plus 
hydrochlorothiazide group (Table 3).78,79
Dual blockade of the RAS
Despite a complete RAS inhibition with ARBs or ACE inhibi-
tors, a number of patients develop or experience progression 
of renal disease.1 As a result, several studies have investigated 
the effects of dual blockade of the RAS in renal outcomes. 
The CALM (Candesartan and Lisinopril Microalbuminuria) 
study aimed to assess and compare the effects of candesartan 
or lisinopril, or both, on BP and urinary albumin excretion 
in patients with microalbuminuria, hypertension, and type 
2 diabetes. At 24 weeks the mean reduction in diastolic BP 
was significantly greater with combination treatment than 
with candesartan or lisinopril alone. Moreover, the reduction 
in urinary albumin-to-creatinine ratio was also greater with 
combination treatment, with a good tolerability profile.80 In 
a 12-month follow-up randomized, clinical trial, lisinopril 
40 mg once daily was compared with dual-blockade treatment 
with candesartan 16 mg once daily and lisinopril 20 mg once 
daily in diabetic patients aged 35–74 years. Reductions in 
systolic BP were similar in both groups (6 mmHg with dual 
blockade versus 2 mmHg with lisinopril; P = 0.10), with 
similar low rates of side effects.81
In a study comparing the efficacy of enalapril 5 mg, losar-
tan 50 mg, or both in normotensive type 2 diabetic patients 
with microalbuminuria, the percentages of reduction in uri-
nary albumin excretion rates at the end of 12 months were 
58%, 59%, and 60%, respectively (P = 0.0001, P = 0.0002, 
P = 0.0003, respectively; P = 0.346 between groups).82 In a 
meta-analysis that studied the effects of dual blockade in the 
prevention of the progression of diabetic nephropathy, dual 
blockade was associated with a more marked proteinuria 
reduction (P = 0.01), a trend towards an increase in serum 
creatinine concentration (6.86 µmol/L; P = 0.09), and an 
increase in potassium levels by 0.2 mmol/L (P , 0.01).83
More recently, the ONTARGET study showed that the 
combination of telmisartan and ramipril, despite reducing BP 
by a few millimeters of mercury more than therapy with either 
ramipril or telmisartan, was associated with more adverse 
events without an increase in benefit.52 With regard to renal 
outcomes, the number of events for the composite primary 
outcome (dialysis, doubling of serum creatinine concentra-
tion, and death) was increased with combination therapy 
(HR, 1.09; 95% CI, 1.01–1.18; P = 0.037). The secondary 
renal outcome (dialysis or doubling of serum creatinine 
concentration) was also more frequent with combination 
therapy (HR, 1.24; 95% CI, 1.01–1.51; P = 0.038).53 However, 
only approximately 4% of patients had overt proteinuria at 
baseline, and worsening of renal outcomes mostly occurred 
in the patients without baseline microproteinuria or frank 
proteinuria. As a result, these data can extend to patients 
with vascular disease or high-risk diabetes without heart 
failure, but they can hardly extend to patients with severe 
renal disease.27 A recent meta-analysis reported that there is a 
lack of evidence at present to support the use of combination 
therapy.84 As reported in the AVOID trial, the dual blockade 
of RAS by aliskiren and losartan in hypertensive patients 
with type 2 diabetic nephropathy reduced the mean urinary 
albumin-to-creatinine ratio beyond BP control.40
Conclusion
To effectively reduce or at least slow the establishment and 
progression of renal disease in the hypertensive population it 
is crucial to attain BP goals. Although BP control rates have 
improved in recent years, mainly because of the increase in 
use of combined therapy, the fact is that many patients do 
not reach BP targets.33
As European guidelines indicate, all major antihyperten-
sive drug classes (ACE inhibitors, ARBs, diuretics, calcium 
channel blockers, and beta-blockers) can be considered for 
treatment, including for diabetic patients.27 However, a num-
ber of studies have shown that treatment with ACE inhibitors, 
ARBs, and, more recently, aliskiren may provide beneficial 
effects beyond BP control, particularly in those with diabetes, 
microalbuminuria, or chronic kidney disease. As the majority 
of these patients will need at least two antihypertensive drugs 
to reach BP goals, the use of RAS inhibitors is a mandatory 
part of antihypertensive therapy in this population.
The best antihypertensive drugs to combine in this setting 
are diuretics and calcium channel blockers. Various studies 
have shown the benefits of combining RAS inhibitors with 
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diuretics or calcium channel blockers in patients with renal 
disease. Canadian guidelines recommend the use of ACE 
inhibitors or ARBs as initial therapy in patients with diabetes 
and albuminuria and, when necessary to attain BP goals, thiaz-
ide diuretics (a loop diuretic should be considered if   creatinine 
level is .150 µmol/L), cardioselective beta-blockers, or long-
acting calcium channel blockers can be added.29 In diabetic 
patients without albuminuria, Canadian guidelines indicate 
that ACE inhibitors, ARBs, dihydropyridine calcium channel 
blockers, or thiazide diuretics are adequate options for starting 
treatment; if the BP target is not achieved, these drugs can be 
combined, except ACE inhibitors and ARBs together.29 Finally, 
in subjects with nondiabetic chronic kidney disease with pro-
teinuria, ACE inhibitors (ARBs if not tolerated) should be used 
as initial therapy, and diuretics as additive therapy.29
However, it is likely that new studies or new post hoc 
analyses may at least partly change these recommendations, 
clarifying the subgroups of patients who will benefit more 
from a combination with a diuretic or from a combination 
with a calcium channel blocker. To date, the RAS inhibitors 
recommended in this context are ACE inhibitors and ARBs. 
Aliskiren, the first available oral direct renin inhibitor, has 
shown promising results. Nonetheless, until the final results 
of the ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using 
Cardiovascular and Renal Disease Endpoints) study (expected 
in 2012) are known, aliskiren could be used in hypertension, 
particularly in combination with other agents.27
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